Study Title: Phase I/II study augmenting TAK-659 action in relapsed/refractory AML by addition of the proteasome inhibitor Ixazomib: Big Ten Cancer Research Consortium BTCRC-HEM17-092
 

• Status: Terminated

• Closed to Accrual at:
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
• Learn more:
  • clinicaltrials.gov: NCT04079738